Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Thioguanine Administered as a Continuous Intravenous Infusion to Pediatric Patients Is Metabolized to the Novel Metabolite 8-Hydroxy-Thioguanine

Brenda J. Kitchen, Asher Moser, Elizabeth Lowe, Frank M. Balis, Brigitte Widemann, Lawrence Anderson, John Strong, Susan M. Blaney, Stacey L. Berg, Michelle O’Brien and Peter C. Adamson
Journal of Pharmacology and Experimental Therapeutics November 1999, 291 (2) 870-874;
Brenda J. Kitchen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asher Moser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Lowe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank M. Balis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigitte Widemann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Anderson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Strong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan M. Blaney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stacey L. Berg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle O’Brien
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter C. Adamson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Thiopurine antimetabolites have been in clinical use for more than 40 years, yet the metabolism of thiopurines remains only partially understood. Data from our previous pediatric phase 1 trial of continuous i.v. infusion of thioguanine (CIVI-TG) suggested that TG was eliminated by saturable mechanism, with conversion of the drug to an unknown metabolite. In this study we have identified this metabolite as 8-hydroxy-thioguanine (8-OH-TG). The metabolite coeluted with the 8-OH-TG standard on HPLC and had an identical UV spectrum, with a λmax of 350 nm. On mass spectroscopy, the positive ion, single quad scan of 8-OH-TG yielded a protonated molecular ion at 184 Da and contained diagnostic ions atm/z 167, 156, 142, and 125 Da. Incubation of TG in vitro with partially purified aldehyde oxidase resulted in 8-OH-TG formation. 8-OH-TG is the predominant circulating metabolite found in patients receiving CIVI-TG and is likely generated by the action of aldehyde oxidase.

Footnotes

  • Send reprint requests to: Peter C. Adamson, M.D., Children’s Hospital of Philadelphia, Abramson Pediatric Research Center, Suite 902, 3516 Civic Center Blvd., Philadelphia, PA 19104. E-mail: adamson{at}emailchop.edu

  • ↵1 Current address: Rainbow Babies and Children’s Hospital, Cleveland, OH 44106.

  • ↵2 Current address: U.S. Food and Drug Administration, Rockville, MD 20850.

  • ↵3 Current address: Texas Children’s Cancer Center, Houston, TX 77030.

  • ↵4 Current address: Children’s Hospital of Philadelphia, Philadelphia, PA 19104.

  • Abbreviations:
    MP
    6-mercaptopurine
    TG
    thioguanine
    8-OH-TG
    8-hydroxy-thioguanine
    CIVI
    continuous intravenous infusion
    AO
    aldehyde oxidase
    • Received April 27, 1999.
    • Accepted August 9, 1999.
  • U.S. Government
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 291 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 291, Issue 2
1 Nov 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Thioguanine Administered as a Continuous Intravenous Infusion to Pediatric Patients Is Metabolized to the Novel Metabolite 8-Hydroxy-Thioguanine
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Thioguanine Administered as a Continuous Intravenous Infusion to Pediatric Patients Is Metabolized to the Novel Metabolite 8-Hydroxy-Thioguanine

Brenda J. Kitchen, Asher Moser, Elizabeth Lowe, Frank M. Balis, Brigitte Widemann, Lawrence Anderson, John Strong, Susan M. Blaney, Stacey L. Berg, Michelle O’Brien and Peter C. Adamson
Journal of Pharmacology and Experimental Therapeutics November 1, 1999, 291 (2) 870-874;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Thioguanine Administered as a Continuous Intravenous Infusion to Pediatric Patients Is Metabolized to the Novel Metabolite 8-Hydroxy-Thioguanine

Brenda J. Kitchen, Asher Moser, Elizabeth Lowe, Frank M. Balis, Brigitte Widemann, Lawrence Anderson, John Strong, Susan M. Blaney, Stacey L. Berg, Michelle O’Brien and Peter C. Adamson
Journal of Pharmacology and Experimental Therapeutics November 1, 1999, 291 (2) 870-874;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Mechanisms of 5-Hydroxytryptamine2A Receptor Activation of the Mitogen-Activated Protein Kinase Pathway in Vascular Smooth Muscle
  • Interactive Role for Neurosteroids in Ethanol Enhancement of γ-Aminobutyric Acid-Gated Currents from Dissociated Substantia Nigra Reticulata Neurons
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics